Clinical Trial: BRAVO is a Phased Outbreak-response Study in the DRC Evaluating ERVEBO(R) Vaccination in ~20,000 Frontline Workers During the 2026 BDV Outbreak, Step A Assesses Real-world Effectiveness, Safety, and Impact on Severe Disease and Mortality, While Generating Evidence for Future BDV Vaccination Strategies

U.S., Oct. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07903350) titled 'BRAVO is a Phased Outbreak-response Study in the DRC Evaluating ERVEBO(R) Vaccination in ~20,000 Frontline Workers During the 2026 BDV Outbreak, Step A Assesses Real-world Effectiveness, Safety, and Impact on Severe Disease and Mortality, While Generating Evidence for Future BDV Vaccination Strategies' on Sept. 18.

Brief Summary: The BRAVO study (Bundibugyo: Respondre Avec la Vaccination, "On est ensemble") was developed in response to the 2026 Bundibugyo virus disease (BVD) outbreak in the Democratic Republic of the Congo (DRC). The study focuses on frontline workers (FLWs), who are at increased risk of infection because of their i...